Can you provide the consensus estimates for PIERIS PHARMACEUTICALS INC next earnings?
The consensus EPS estimate for the next earnings of PIERIS PHARMACEUTICALS INC (PIRS) is -0.06 USD and the consensus revenue estimate is 1.09M USD.
PIERIS PHARMACEUTICALS INC (PIRS) Forecast, Price Target & Analyst Ratings
NASDAQ:PIRS • US7207952026
Current stock price
13.6 USD
-2.53 (-15.69%)
At close:
13.26 USD
-0.34 (-2.5%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PIERIS PHARMACEUTICALS INC (PIRS).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q4 / 2024
- EPS Estimate
- -$0.06
- Revenue Estimate
- 1.09M
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $13.60 to mean target of N/A, Based on 6 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
43.33%
PIRS was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about PIRS.
In the previous month the buy percentage consensus was at a similar level.
PIRS was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q4 / 2024
- EPS Estimate
- -$0.06
- Revenue Estimate
- 1.09M
- Revenue Q2Q
- -16.09%
- EPS Q2Q
- 50.00%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates 2024 - 2030
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 31.418M 7.14% | 25.902M -17.56% | 42.81M 65.28% | 6.758M -84.21% | -100.00% | 17.85M | 193.39M 983.42% | 213.49M 10.39% | 235.52M 10.32% | ||
| EBITDA YoY % growth | -49.372M -56.19% | -40.704M 17.56% | -13.94M 65.75% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -51.831M -52.80% | -43.474M 16.12% | -15.844M 63.56% | -22.282M -40.63% | -27.151M -21.85% | -28.647M -5.51% | -42.33M -47.77% | 148.1M 449.87% | 170.85M 15.36% | 194.41M 13.79% | |
| Operating Margin | -164.97% | -167.84% | -37.01% | -329.71% | N/A | N/A | -237.14% | 76.58% | 80.03% | 82.55% | |
| EPS YoY % growth | -55.37 -1.79% | -36.00 34.99% | N/A 99.01% | -0.20 42.86% | -0.30 -45.00% | -0.32 -6.90% | N/A | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 24 | |
|---|---|
| EPS Q2Q % growth | -0.06 50.00% |
| Revenue Q2Q % growth | 1.09M -16.09% |
| EBITDA Q2Q % growth | N/A |
| EBIT Q2Q % growth | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
3.67%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-25.99%
Revenue Next 5 Year
42.76%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
PIERIS PHARMACEUTICALS INC / PIRS Forecast FAQ
What is the number of analysts for PIRS stock?
The number of analysts covering PIERIS PHARMACEUTICALS INC (PIRS) is 6.